Assessing Depression in a Geriatric Cancer Population

NCT00580476 | Completed

• 1 other identifier: 06-100
• Study Type: observational
• Target: 201
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to learn more about how we measure depression in elderly cancer patients (patients aged 70 and older). Depression is one of the most common causes of emotional distress in the elderly and continues to be under-recognized. This is a problem because depression can have a negative impact on quality of life. The symptoms of depression are linked to poor health outcomes and higher costs of health care. In fact, depression is one of the top five concerns facing the elderly today.

Conditions

Breast Cancer; Prostate Cancer

Keywords

Breast Cancer; Prostate Cancer

Outcome Measures

Primary Outcomes (1)

• Test the sensitivity and specificity of the Geriatric Depression Scale-Short Form and two other widely used assessments of depression to detect major and minor depression in a geriatric breast and prostate cancer population.

  2 years

Secondary Outcomes (1)

• To develop a cut-off score for the GDS that is specific to a cancer population.

  2 years

Study Arms (2)

1

150 patients will be women with breast cancer (75 early stage and 75 late stage)

2

150 will be men with prostate cancer (75 early stage and 75 late stage)

Eligibility Criteria

• Age: 70 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Geriatric Patients with Breast or Prostate Cancer

You may qualify if:

• Age 70 and older
• Diagnosis of early or late stage prostate cancer, or diagnosis of early or late stage breast cancer
• Actively engaged in one of the following cancer treatments: chemotherapy, radiation therapy, hormone therapy
• Able to provide informed consent
• Ability to converse, write and read English

You may not qualify if:

• Major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• City of Hope National Medical Center: collaborator

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Breast Neoplasms; Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Christian Nelson, Ph.D.

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 19, 2007
• First Posted: December 24, 2007
• Study Start: September 12, 2006
• Primary Completion: September 5, 2024
• Study Completion: September 5, 2024
• Last Updated: September 19, 2024

Record last verified: 2024-09

Locations

US (1)